<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216657</url>
  </required_header>
  <id_info>
    <org_study_id>S379 SUMA</org_study_id>
    <nct_id>NCT01216657</nct_id>
  </id_info>
  <brief_title>Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma</brief_title>
  <official_title>An Open-label, Uncontrolled Phase II Trial of Single Agent Sunitinib (SU 11248) for Patients With Chemo-refractory Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Krankenhaus Nordwest</source>
  <brief_summary>
    <textblock>
      Sunitinib is a novel small molecule receptor tyrosine kinase inhibitor with direct antitumor&#xD;
      effects as well as antiangiogenetic activity. Preclinical and clinical data for Sunitinib and&#xD;
      data about angiogenesis and growth regulation in melanoma suggest the activity of Sunitinib&#xD;
      in melanoma. This study will investigate the efficacy, safety and tolerability of Sunitinib&#xD;
      as palliative treatment in chemo-refractory metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single agent 2-step phase 2 study with a one-year follow-up to evaluate the&#xD;
      antitumor activity of Sunitinib administered in treatment cycles of 6 weeks duration (4 weeks&#xD;
      treatment and 2 weeks rest) in patients with chemo-refractory melanoma. If the first step&#xD;
      shows sufficient efficacy and tolerability the study will continue to step 2. Treatment will&#xD;
      continue for 9 months or until disease progression or until intolerable adverse events occur.&#xD;
      Subsequently the patients will be followed up for 1 year. Tumor assessment will be performed&#xD;
      at baseline, at the end of cycle 1,2,3 and subsequently at the end of every uneven cycle&#xD;
      (5,7,9,…).&#xD;
&#xD;
      A total of 40 patients will be enrolled in this trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow recruitment&#xD;
  </why_stopped>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical benefit rate cycle 1-3</measure>
    <time_frame>tumor assessment every 6 weeks</time_frame>
    <description>clinical benefit rate defined as a CR + PR + SD &gt; 4 months duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical benefit rate cycle 4 and more</measure>
    <time_frame>tumor assessment every 12 weeks</time_frame>
    <description>clinical benefit rate defined as a CR + PR + SD &gt; 4 months duration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate cycle 1-3</measure>
    <time_frame>tumor assessment every 6 weeks</time_frame>
    <description>response rate defined as CR+PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>follow-up one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>follow-up for one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate cycle 4 and more</measure>
    <time_frame>every 12 weeks</time_frame>
    <description>response rate defined as CR+PR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Chemo-refractory Melanoma</condition>
  <arm_group>
    <arm_group_label>sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg Sunitinib daily for 4 weeks, then 2 weeks without treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>50 mg oral, daily, for 4 weeks, then 2 weeks without treatment, repeat at d43</description>
    <arm_group_label>sunitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients aged 18 years and older.&#xD;
&#xD;
          -  Diagnosis of unresectable (Stage III) or metastatic (Stage IV), histologically or&#xD;
             cytologically proven, melanoma without clinically meaningful surgical or&#xD;
             radiotherapeutical options except for mucosal or ocular origin of the primary tumor.&#xD;
&#xD;
          -  Subjects must have completed a first or second line chemotherapy or be progressed&#xD;
             under chemotherapeutic treatment. The previous treatment must have included DTIC alone&#xD;
             or in combination&#xD;
&#xD;
          -  Performance status of 0 to 2 on the ECOG scale&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks.&#xD;
&#xD;
          -  Patients must be able to swallow Sunitinib capsules.&#xD;
&#xD;
          -  Evidence of measurable disease according to the RECIST criteria&#xD;
&#xD;
          -  Prior radiation therapy allowed if completed at least 2 weeks and any major surgery&#xD;
             allowed if completed at least 4 weeks prior to first dose of Sunitinib.&#xD;
&#xD;
          -  Resolution of all acute toxic side effects of prior therapy or surgical procedures to&#xD;
             grade &lt; 1 NCI-CTC (except for laboratory values).&#xD;
&#xD;
          -  Adequate organ function including the following:&#xD;
&#xD;
               -  platelets &gt; 100 x 109/L&#xD;
&#xD;
               -  hemoglobin &gt; 8 g/dl&#xD;
&#xD;
               -  absolute neutrophils count (AGC) &gt; 1.5 x 109/L.&#xD;
&#xD;
          -  Hepatic:&#xD;
&#xD;
               -  bilirubin &lt;=1.5 times upper limit of normal (ULN)&#xD;
&#xD;
               -  aspartate transaminase (AST) and alanine transaminase (ALT) &lt;=2.5 times normal&#xD;
                  (AST and ALT &lt;=5.0 times normal is acceptable if liver function abnormalities are&#xD;
                  due to underlying malignancy).&#xD;
&#xD;
          -  INR &lt; 1.5 or a PTT within normal limits.&#xD;
&#xD;
          -  Subjects must not have any evidence of a bleeding diathesis.&#xD;
&#xD;
          -  Renal:&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5 x ULN&#xD;
&#xD;
               -  serum calcium &lt; 1.2 mg/dl.&#xD;
&#xD;
          -  Pancreatic:&#xD;
&#xD;
          -  Serum lipase and amylase within normal range.&#xD;
&#xD;
          -  Signed and dated informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with ras-raf-MEK-ERK signaling pathway inhibitors (including&#xD;
             trastuzumab, sorafenib, farnesyl transferase inhibitors or MEK inhibitors), or&#xD;
             treatment with drugs which target VEGF (such as bevacizumab).&#xD;
&#xD;
          -  Radiotherapy, except palliative radiotherapy during study participation as described.&#xD;
&#xD;
          -  Known active infection (i.e. HIV, chronic hepatitis B or C, at the discretion of the&#xD;
             investigator)&#xD;
&#xD;
          -  History of organ allograft or stem cell transplantation.&#xD;
&#xD;
          -  Coexisting second malignancy (excluding basal or squamous cell carcinoma of the skin,&#xD;
             superficial bladder cancer and in situ carcinoma of the cervix with no evidence of&#xD;
             recurrence) or history of prior malignancy&#xD;
&#xD;
          -  Bowel obstruction, history or presence of inflammatory enteropathy or extensive&#xD;
             intestinal resection (&gt; hemicolectomie or extensive small intestine resection with&#xD;
             chronic diarrhea), Crohn's disease, ulcerative colitis.&#xD;
&#xD;
          -  Current history of chronic diarrhea defined as persisting diarrhea for more than 3&#xD;
             weeks at study entry due to any reason.&#xD;
&#xD;
          -  Any of the following events prior to starting the trial treatment: *clinically evident&#xD;
             congestive heart failure, as defined by New York Health Association (NYHA) &gt; class II&#xD;
&#xD;
               -  Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2&#xD;
&#xD;
               -  Atrial fibrillation of any grade, or prolongation of the QTc interval to &gt;450&#xD;
                  msec for males or &gt;470 msec for females.&#xD;
&#xD;
          -  Subjects on beta-blockers and digoxin must be monitored closely&#xD;
&#xD;
          -  QT-interval &gt; 450 msec&#xD;
&#xD;
          -  Risk factors for torsade-de-pointes-tachycardia (i.e.. Hypokalaemia, congenital&#xD;
             Long-QT-syndrome)&#xD;
&#xD;
          -  Active coronary artery disease or ischemia (myocardial infarction within the last 6&#xD;
             months prior to study entry)&#xD;
&#xD;
          -  Coronary/peripheral artery bypass graft&#xD;
&#xD;
          -  Cerebrovascular accident or transient ischemic attack&#xD;
&#xD;
          -  Active disseminated intravascular coagulation, or history of clinically significant&#xD;
             bleeding within the past 6 months, including gross hemoptysis or haematuria, or&#xD;
             underlying coagulopathy&#xD;
&#xD;
          -  Hypertension that cannot be controlled by medications (&gt;150/100 mmHg despite optimal&#xD;
             medical therapy).&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition, or laboratory&#xD;
             abnormality that would impart, in the judgment of the investigator, excess risk&#xD;
             associated with trial participation or trial drug administration, or which, in the&#xD;
             judgment of the investigator, would make the patient inappropriate for entry into the&#xD;
             trial.&#xD;
&#xD;
          -  Participation in any other clinical trial within the last 3 weeks.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Known allergic/hypersensitivity reaction to any of the components of the treatment, or&#xD;
             known drug abuse/alcohol abuse.&#xD;
&#xD;
          -  Active CNS metastatic or meningeal tumors.&#xD;
&#xD;
          -  Patients with seizure disorders requiring medication (such as antiepileptics, the use&#xD;
             of carbamazepine, phenytion an phenobarbital is prohibited).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elke Jäger, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus Nordwest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>sunitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

